Dexcom Archives - Page 13 of 14 - Medical Design Sourcing

DTW Podcast: CEO Petrovic explains how Insulet is switching people to `Pods

Insulet CEO Shacey Petrovic says she didn’t jump immediately at the chance to join the company.

In an interview with the DeviceTalks Weekly Podcast, Petrovic, who was serving as CEO of a women’s health company when CEO-Patrick Sullivan, her former boss at Cytyc, called her with an offer to serve as Insulet’s chief commercial officer

“I said, `Well, Pat, I’m a CEO now, you know, didn’t you hear?,” she joked.

A chief commercial officer role might be seen as a backward step from CEO, but Sullivan framed the question differently. He told Petrovic that he came out of retirement to take the CEO role and didn’t want to a long stint as CEO. “He said, `This could be your opportunity to eventually run a public company. If it goes well, I need a successor, the technology is remarkable, and together we can fix this problem.’”

A path the CEO role at a publicly traded company was certainly appealing. But Petrovic had more personal reason for the jo…

How CGM tech has advanced in the 21st century

The rapid evolution of the continuous glucose monitor (CGM) has brought flexibility and convenience to diabetes control.

Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history.

Efforts to manage glucose kicked off in earnest when researchers began measuring glucose in urine in the mid-1800s. Scientists’ ability to do so steadily improved over the years, but urine glucose testing wasn’t commercialized until 1908, establishing a foundation for diabetes care.

Elkhart, Ind.–based Ames Company refined the process in 1945 with the introduction of Clinitest reagent tablets, which are still commercially available, albeit from Bayer. The company would introduce the first blood glucose test strip in 1965. The Dextrostix-branded strips were intended for use in doctors’ offices.

In the 1970s, Ames developed a device known as the Ames Reflectance Meter to m…

How CGM tech has advanced in the 21st century

The rapid evolution of the continuous glucose monitor (CGM) has brought flexibility and convenience to diabetes control.

Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history.

Efforts to manage glucose kicked off in earnest when researchers began measuring glucose in urine in the mid-1800s. Scientists’ ability to do so steadily improved over the years, but urine glucose testing wasn’t commercialized until 1908, establishing a foundation for diabetes care.

Elkhart, Ind.–based Ames Company refined the process in 1945 with the introduction of Clinitest reagent tablets, which are still commercially available, albeit from Bayer. The company would introduce the first blood glucose test strip in 1965. The Dextrostix-branded strips were intended for use in doctors’ offices.

In the 1970s, Ames developed a device known as the Ames Reflectance Meter to m…

MedTech 100 roundup: Rise to new heights continues

The medtech industry hit another high as 2021 continues to bring strong performances out of some of the biggest companies around.

MassDevice‘s MedTech 100 index ended the week (Feb. 12) at 110.63 points, marking a 2.2% rise from the 108.23-point mark set at the end of the previous week (Feb. 5).

The final mark for the week sets an all-time best for the index, which had previously reached 106.81 points on Jan. 8, then 107.4 points on Jan. 20 before besting itself again with last week’s finish. The rise has been considerably impressive given that the index had never reached even the 100-point mark before November 2020.

Medtech’s latest rise means the index has risen 19.8% from the pre-COVID-19 pandemic high of 92.32, set on Feb. 19, 2020. Additionally, the industry has very much rebounded from its lowest place, a 62.13-point mark at the start of the pandemic on March 23, 2020. Since that point, the industry has jumped 78.1%.

Medtech’s performa…

Dexcom Q4 earnings miss by a penny — but revenue up 23%

Dexcom (NSDQ:DXCM) this evening reported mixed Q4 2020 results and reiterated a fiscal year 2021 revenue guidance that is slightly below Wall Street projections.

The San Diego–based continuous glucose monitor company reported profits of $355.2 million, or $3.48 per share, on sales of $568.9 million for the three months ended Dec. 31, 2020, nearly quadrupling the bottom line on 23% sales growth compared with Q4 2019.

Adjusted to exclude one-time items, earnings per share were 91¢, a penny behind The Street, where analysts were looking for EPS of 92¢ on sales of $552.88 million.

Get the full story on our sister site Drug Delivery Business News.

Looking back at two decades of CGM advances

The Freestyle Libre 2 from Abbott

Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history.

Attempts to manage glucose kicked off in earnest when researchers began measuring glucose in urine in the mid-1800s. Scientists’ ability to do so steadily improved over the years, but urine glucose testing wasn’t commercialized until 1908, establishing a foundation for diabetes care.

Elkhart, Ind.-based Ames Company refined the process in 1945 with the introduction of Clinitest reagent tablets, which are still commercially available, albeit from Bayer (ETR:BAYN). The company would introduce the first blood glucose test strip in 1965. The Dextrostix-branded strips were intended for use in doctors’ offices.

Get the full story on our sister site, Drug Delivery Business News.

DTW Podcast: CEO Johnson on entrepreneurship, upcoming MedtechColor Pitch Contest; Krum handicaps medtech Q4

In this episode of the DeviceTalks Weekly Podcast, Angelique Johnson, CEO of MEMstim, shares her “accidental entrepreneur” story and how it has enabled her the help others pursuing the same dream.

Also, Johnson, co-founder of MedtechColor, an organization seeking to further the advancement of people of color in the medical device industry, details the group’s goals and invites entrepreneurs of color to apply for the group’s Pitch Contest.

The deadline is Feb. 5. Go to medtechcolor.org for more information.

Truist Securities Managing Director Kaila Krum answers questions about medtech’s Q4 performance, diving deeper on Stryker and other companies.

Krum also shares details on a survey conducted by the research team that sought to answer the question – when will hospitals start seeing elective patients again.

Pharma Editor Brian Buntz returns to tell his story of his 10-days wearing a continuous glucose monitor from Dexcom. Buntz wrote …

How CGMs can inspire lifestyle changes

Dexcom G6 transmitter

As an early adopter of fitness trackers such as the FitBit, I’ve long appreciated the power of health data. But my recent experience with a continuous glucose monitor (CGM) has done far more to inspire me to look after my health — even as a nondiabetic.

I had heard about the potential of such technology before from the cardiologist Dr. Eric Topol, who serves on the board of Dexcom (NASDAQ:DXCM), and the entrepreneur Tim Ferriss, who has discussed using the technology as a non-diabetic to optimize weight loss and muscle gain.

But I have only recently had the chance to evaluate CGM as part of Dexcom’s “Hello Dexcom” sample program that enables patients to try out the company’s G6 CGM at no cost. The goal of the program is to increase awareness among healthcare providers and consumers.

Get the full story from our sister site, Drug Delivery Business.

How CGMs can inspire lifestyle changes

Dexcom G6 transmitter

As an early adopter of fitness trackers such as the FitBit, I’ve long appreciated the power of health data. But my recent experience with a continuous glucose monitor (CGM) has done far more to inspire me to look after my health — even as a nondiabetic.

I had heard about the potential of such technology before from the cardiologist Dr. Eric Topol, who serves on the board of Dexcom (NASDAQ:DXCM), and the entrepreneur Tim Ferriss, who has discussed using the technology as a non-diabetic to optimize weight loss and muscle gain.

But I have only recently had the chance to evaluate CGM as part of Dexcom’s “Hello Dexcom” sample program that enables patients to try out the company’s G6 CGM at no cost. The goal of the program is to increase awareness among healthcare providers and consumers.

Get the full story from our sister site, Drug Delivery Business.

How CGMs can inspire lifestyle changes

G6 from Dexcom

As an early adopter of fitness trackers such as the FitBit, I’ve long appreciated the power of health data. But my recent experience with a continuous glucose monitor (CGM) has done far more to inspire me to look after my health — even as a nondiabetic.

I had heard about the potential of such technology before from the cardiologist Dr. Eric Topol, who serves on the board of Dexcom (NASDAQ:DXCM), and the entrepreneur Tim Ferriss, who has discussed using the technology as a non-diabetic to optimize weight loss and muscle gain.

But I have only recently had the chance to evaluate CGM as part of Dexcom’s “Hello Dexcom” sample program that enables patients to try out the company’s G6 CGM at no cost. The goal of the program is to increase awareness among healthcare providers and consumers.

The G6 device, pictured above, provides blood glucose readings every 5 minutes for 10 days via a smartphone app or dedicated receiver.

Brian Buntz

Mode…

How continuous glucose monitors have transformed the diabetes landscape

G6 applicator from Dexcom

Continuous glucose monitors (CGMs) are among the most potent diabetes management tools to emerge in recent decades.

FDA approved the first professional CGM in 1999, and the technology has evolved swiftly since then. Current models beam data via Bluetooth to smartphones (plus the Apple Watch) and the cloud, enabling patients to explore their blood glucose readings in an app or via downloadable PDFs.

“Decades ago, we were still checking urine sugars,” said Dr. Egils Bogdanovics, a Connecticut-based endocrinologist. “In the early 1980s, fingerstick blood glucose monitors came out. That was a big deal — a revolution in diabetes,” Bogdanovics recalled.

Get the full story from our sister publication, Drug Delivery Business.

These medtech stocks performed the best in 2020

(From Ishant Mishra on Unsplash)

While 2020 did not go as planned for anyone, with the twists and turns came opportunities for medtech companies to power forward.

Innovations came both as a result of the COVID-19 pandemic and perhaps in spite of the challenges brought on by the virus, highlighted by the increased efforts to produce vaccines and testing while pivoting to artificial-intelligence-based and remote care.

Companies like Moderna arose from nowhere, climbing from a share price of $19.52 to $104.47 over the course of the year as it established itself as a frontronner in the race to get a COVID-19 vaccine to the public, eventually becoming the second vaccine authorized in the U.S.

MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — has hit new heights over the course of 2020, indicating the upward trajectory of the industry. Over the course of the year, the index grew from a total of $86.8…